Cook Regentec, focused on developing research and clinical tools to advance regenerative medicine therapies from the lab to the patient, and Asymptote Ltd., specialists in cryochain for regenerative medicine, today announced the launch of the CellSeal® Automated Thawing System. The new system, which has been developed as part of a collaboration between the two companies, provides users with thorough control in the thawing of cryogenically frozen cells, a critical step in the delivery of cell and gene therapies.
The CellSeal® Automated Thawing System solves a vital and overlooked aspect of cell-based therapy development. The current practice of thawing these potentially fragile, living therapies relies on a manual process using a water bath. The new system works through dry conduction with no need of water, a potential source of contamination, and provides an effective, reliable and scalable solution which supports Good Manufacturing Practice (GMP) requirements.
The CellSeal® Automated Thawing System has demonstrated performance. In a recent study with mesenchymal stem cells (MSC), the system consistently equaled viability results obtained from water bath thawing. The system’s effectiveness comes from the extraordinary control it provides over the thawing process. Therapy manufacturers can tune a thaw profile to suit the specific needs of their cellular therapy, then lock the profile down for one-touch repeatability. The system removes any user subjectivity by detecting the precise thaw end-point—extremely difficult to achieve using the standard water bath process. The technology offers manufacturers consistent control over the thawing process of their cell therapy.
An important feature of the new system is instant access to vital data. Until this new system, the collection and collation of data from thaw sites, often using paper records, could produce significant challenges to cell and gene therapy manufacturers. Now, data recording in each CellSeal® Automated Thawing System captures a record of the thaw process. With appropriate software, hardware and connectivity, this data can be viewed anywhere in the world to validate and implement a manufacturer’s end-to-end thawing protocol.
“We created our CellSeal® product line to support cell and gene therapy companies through every bioprocessing step,” explained Brad King, Director of Advanced Laboratory Products at Cook Regentec. “Thawing of cryopreserved therapies often happens outside the lab in conditions that up to now have been very difficult to control; thaw-site personnel have had to take great care to avoid contamination risks from the use of warm water… The CellSeal Automated Thawing System makes it easy to ensure an effective, controlled and auditable thaw.”
Cook partnered with Asymptote for the technology behind the thawing system because of their long established cryopreservation expertise and innovative cryochain technologies for regenerative medicine.
“Today’s announcement builds on thawing technology we have been working on for over two years in collaboration with The Cell and Gene Therapy Catapult,” said John Morris, Asymptote CEO. “Over that period, Asymptote built many different thawing engines for testing at the Catapult labs and captured requirements from a wide cross-section of stakeholders across the industry. By partnering that foundation with Cook Regentec’s development of closed-system vials, we’re able to offer the industry a unique level of control over the thawing process.“
The CellSeal® Automated Thawing System will be available for shipment in January 2017.